SCHEMBL2234591

SCHEMBL2234591

COC(=O)NN(C(=O)Oc1ccccc1)c1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.48
LMNA P02545 2/20 0.48
PTGES O14684 1/20 0.47
ALDH1A1 P00352 5/20 0.46
MAPT P10636 4/20 0.46
TDP1 Q9NUW8 2/20 0.46
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
THRB P10828 1/20 0.46
GFER P55789 1/20 0.46
ATM Q13315 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.41
TAAR1 Q96RJ0 1/20 0.41
LIPE Q05469 2/20 0.40
POLB P06746 2/20 0.39
TP53 P04637 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2234676 0.94 L3MBTL1 (0.54) L3MBTL1LMNAPTGESALDH1A1MAPT
SCHEMBL2234801 0.90 PTGES (0.56) L3MBTL1PTGESALDH1A1MAPTTDP1
SCHEMBL2237040 0.87 PTGES (0.48) L3MBTL1PTGESALDH1A1MAPTTDP1
SCHEMBL2236288 0.86 PTGES (0.47) L3MBTL1PTGESALDH1A1MAPTTDP1
SCHEMBL27842386 0.83 HSD17B1 (0.44) L3MBTL1LMNAALDH1A1MAPTMEN1
SCHEMBL28793433 0.83 PTGES (0.44) L3MBTL1PTGESALDH1A1MAPTTDP1
SCHEMBL2233608 0.82 ALDH1A1 (0.57) L3MBTL1LMNAPTGESALDH1A1MAPT
SCHEMBL27859909 0.80 MTNR1A (0.47) L3MBTL1PTGESALDH1A1MAPTTDP1
SCHEMBL2236294 0.79 ATM (0.47) L3MBTL1LMNAALDH1A1MAPTMEN1
SCHEMBL2236717 0.76 ALDH1A1 (0.53) L3MBTL1PTGESALDH1A1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102186811-B Process for producing bisoxazolinone compound and intermediate thereof SUMITOMO CO LTD 2013-07-24 CN disclosed
US-8299264-B2 Method for producing oxadiazolinone compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-30 US disclosed
CN-102186811-A Process for producing bisoxazolinone compound and intermediate thereof SUMITOMO CHEMICAL CO 2011-09-14 CN disclosed
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-25 US disclosed
EP-2357167-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2011-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF AHR, CYP1B1, AR L3MBTL1 3727/4885LMNA 2407/4885PTGES 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.